Novo’s CEO champions “record-breaking start” for Wegovy pill in US market - Pharmaceutical Technology

Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly. Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly. Oral Wegovy has been prescribed more than 2 million times since its January launch. Photo by aprott/iStock via Getty Images. Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy pill is offering a route to greener financial pastures. In its Q1 results, Novo touted a strong early showing for the oral glucagon-like peptide-1 receptor agonists (GLP-1RA),…

Source: Pharmaceutical Technology